Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Press releases

September 26, 2022 | REGULATORY

Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia’s IMMray PanCan-d test

Read press release
August 24, 2022 | REGULATORY

Immunovia Publishes Interim Report Jan-June 2022

Read press release
August 23, 2022

Immunovia to present at Gilmartin Group’s Emerging Growth Company Showcase

Read press release
August 22, 2022

Invitation to Immunovia’s Q2 presentation

Read press release
August 11, 2022

Immunovia, Inc. Issued Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray™ PanCan-d test

Read press release
July 5, 2022

CPT PLA Code for the IMMray™ PanCan-d test approved

Read press release
June 30, 2022

The PanDIA-1 study, for early detection of pancreatic cancer in newly onset type 2 diabetics, moves into next phase

Read press release
June 27, 2022

Invitation to Immunovia’s Presentation of PanFAM-1 Results

Read press release
June 27, 2022 | REGULATORY

PanFAM-1 Results Partly Inconclusive

Read press release
June 2, 2022 | REGULATORY

Philipp Mathieu appointed CEO of Immunovia AB

Read press release
May 23, 2022

Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from Pennsylvania and Maryland Departments of Health making IMMray™ PanCan-d test available in 48 US states

Read press release
May 17, 2022

Immunovia, Inc. achieves Clinical Laboratory Licensure from Rhode Island Dept of Health making IMMray™ PanCan-d test available in 46 US states

Read press release
1 3 4 5 6 7 27